Abstract Objective To investigate the effects of calcium-sensitive receptors (CaSR) on the expression of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) and cortisol concentration in a neonatal mouse model of persistent pulmonary hypertension (PPH). Methods Fifty-six newborn C57BL/6 mice were randomly divided into a control group (n=14), a PPH group (n=14), an agonist group (n=14), and an inhibitor group (n=14). The mice in the PPH, agonist, and inhibitor groups were exposed to a 12% oxygen concentration, and the agonist group and inhibitor group were given CaSR agonist (GdCl3, 16 mg/kg) and CaSR antagonist (NPS2390, 1 mg/kg) intraperitoneally once a day, respectively. The mice in control group were exposed to air, and then injected with an equal volume of normal saline as those in the PPH group every day. All mice were treated for 14 days. Morphological examination of heart and lung tissues was performed using hematoxylin-eosin staining. The expression levels of 11β-HSD2 mRNA and 11β-HSD2 protein in lung tissues were measured by qRT-PCR and Western blot respectively. Brain natriuretic peptide (BNP) and cortisol levels in lung tissues were determined using ELISA. Results Compared with the control group, the PPH group had significantly increased pulmonary artery wall thickness (WT%), ratio of right to left ventricular thickness (RV/LV), alveolar mean linear intercept, and BNP concentration and a significantly reduced radial alveolar count (P < 0.05); compared with the PPH group, the agonist group showed significant increases in WT% and BNP concentration, while the inhibitor group showed significant reductions in the two indicators (P < 0.05). Compared with the control group, the PPH group showed significant reductions in the expression levels of 11β-HSD2 mRNA and 11β-HSD2 protein, but a significant increase in cortisol concentration (P < 0.05); compared with the PPH group, the agonist group had significantly lower expression levels of 11β-HSD2 mRNA and 11β-HSD2 protein, but a significant higher cortisol concentration, while the inhibitor group showed opposite changes in these indicators (P < 0.05). Conclusions CaSR may control the development and progression of PPH in newborn mice by regulating the expression of 11β-HSD2 and cortisol concentration.
CHEN Zhi-Wen,LI Xiang,WU Bing-Xia et al. Effects of calcium-sensitive receptors on 11β-hydroxysteroid dehydrogenase type 2 and cortisol in neonatal mice with persistent pulmonary hypertension[J]. CJCP, 2019, 21(11): 1124-1130.
CHEN Zhi-Wen,LI Xiang,WU Bing-Xia et al. Effects of calcium-sensitive receptors on 11β-hydroxysteroid dehydrogenase type 2 and cortisol in neonatal mice with persistent pulmonary hypertension[J]. CJCP, 2019, 21(11): 1124-1130.
Del Rey Hurtado de Mendoza B, Sánchez-de-Toledo J, Bobillo Perez S, et al. Lung ultrasound to assess the etiology of persistent pulmonary hypertension of the newborn (LUPPHYN Study):a pilot study[J]. Neonatology, 2019, 116(2):140-146.
[2]
Kibe M, Ibara S, Inagaki H, et al. Lethal persistent pulmonary hypertension of the newborn in Bohring-Opitz syndrome[J]. Am J Med Genet A, 2018, 176(5):1245-1248.
[3]
Ng QX, Venkatanarayanan N, Ho CYX, et al. Selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn:an update meta-analysis[J]. J Womens Health (Larchmt), 2019, 28(3):331-338.
[4]
Burford NG, Webster NA, Cruz-Topete D. Hypothalamicpituitary-adrenal axis modulation of glucocorticoids in the cardiovascular system[J]. Int J Mol Sci, 2017, 18(10). pii:E2150.
[5]
Chen L, Guilmette J, Luo ZC, et al. Placental 11β-HSD2 and cardiometabolic health indicators in infancy[J]. Diabetes Care, 2019, 42(5):964-971.
[6]
Babooa N, Shi WJ, Chen C. Factors relating caesarean section to persistent pulmonary hypertension of the newborn[J]. World J Pediatr, 2017, 13(6):517-527.
Ambalavanan N, Bulger A, Murphy-Ullrich J, et al. Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling[J]. Pediatr Res, 2005, 57(5 Pt 1):631-636.
[11]
甄毅岚. 钙敏感受体在小鼠缺血性脑卒中的作用及机制[D]. 合肥:安徽医科大学, 2014.
[12]
Knudsen L, Weibel ER, Gundersen HJ, et al. Assessment of air space size characteristics by intercept (chord) measurement:an accurate and efficient stereological approach[J]. J Appl Physiol (1985), 2010, 108(2):412-421.
[13]
Cooney TP, Thurlbeck WM. The radial alveolar count method of Emery and Mithal:a reappraisal 1-postnatal lung growth[J]. Thorax, 1982, 37(8):572-579.
[14]
Alano MA, Ngougmna E, Ostrea EM Jr, et al. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn[J]. Pediatrics, 2001, 107(3):519-523.
[15]
Nakamura H, Zimmer J, Lim T, et al. Increased CaSR and TRPC6 pulmonary vascular expression in the nitrofen-induced model of congenital diaphragmatic hernia[J]. Pediatr Surg Int, 2018, 34(2):211-215.
Kossintseva I, Wong S, Johnstone E, et al. Proinflammatory cytokines inhibit human placental 11beta-hydroxysteroid dehydrogenase type2 activity through Ca2+ and cAMP pathways[J]. Am J Physiol Endocrinol Metab, 2006, 290(2):E282-E288.
[18]
Hardy DB, Dixon SJ, Narayanan N, et al. Calcium inhibits human placental 11beta-hydroxysteroid dehydrogenase type 2 activity[J]. Biochem Biophys Res Commun, 2001, 283(4):756-761.
Zhang L, Zhou J, Jing Z, et al. Glucocorticoids regulate the vascular remodeling of aortic dissection via the p38 MAPK-HSP27 pathway mediated by soluble TNF-RII[J]. EBioMedicine, 2018, 27:247-257.
[21]
Ong SL, Whitworth JA. How do glucocorticoids cause hypertension:role of nitricoxide deficiency, oxidative stress, and eicosanoids[J]. Endocrinol Metab Clin North Am, 2011, 40(2):393-407.
[22]
Vahe C, Benomar K, Espiard S, et al. Diseases associated with calcium-sensing receptor[J]. Orphanet J Rare Dis, 2017, 12(1):19.
[23]
Lee JW, Park HA, Kwon OK, et al. NPS 2143, a selective calcium-sensing receptor antagonist inhibits lipopolysaccharideinduced pulmonary inflammation[J]. Mol Immunol, 2017, 90:150-157.
[24]
Zhou C, Ye F, Wu H, et al. Recent advances in the study of 11β-hydroxysteroid dehydrogenase type 2(11β-HSD2) inhibitors[J]. Environ Toxicol Pharmacol, 2017, 52:47-53.
